Edgar Filing: Ramasastry Saira - Form 4

anter Cair

ъ

Form 4										
January 31, 2		татес	SECUD	ітібс а	ND EV(JCE C	COMMISSION		PPROVAL
	UNITED) IAILS		hington,			NGE U	.01v11v1155101N	OMB Number:	3235-0287
Check this box if no longer subject to Section 16. SECURITIES							January 3 Expires: 20 Estimated average burden hours per response 0			
(Print or Type R	Responses)									
1. Name and A Ramasastry	ddress of Reporting F Saira	Person <u>*</u>	Symbol	Name and S THERA			-	5. Relationship of Issuer (Check	Reporting Pers	
(Last) 316 GOLDE	(First) (MEN HILL DR.	liddle)	3. Date of (Month/D) 01/29/20	•	ansaction			X Director Officer (give below)		Owner er (specify
PORTOLA	(Street) VALLEY, CA 94	.028		ndment, Da th/Day/Year	-			6. Individual or Jo Applicable Line) _X_ Form filed by C Form filed by M	One Reporting Pe	rson
(City)		Zip)	T 11	IN D	• .• .			Person		
1.Title of Security (Instr. 3)	.Title of 2. Transaction Date 2A. Deer decurity (Month/Day/Year) Execution Instr. 3) any			on Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of
Common Stock	01/29/2018			Code V U	Amount 12,221	(A) or (D) D	Price \$ 0.67	Transaction(s) (Instr. 3 and 4) 27,779	D	
Common Stock	01/31/2018			D	27,779	D	(1) (2)	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Ramasastry Saira - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option	\$ 0.32	01/31/2018		D	5,000	(3)(4)	09/15/2027	Common Stock	5,000	

Reporting Owners

	Relationsh	ips	
Director	10% Owner	Officer	Other
Х			
	01/31/2	2018	
	Date		
		Director 10% Owner X 01/31/2	

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Consists of restricted stock units. Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated December 11, 2018, by and among Repros Therapeutics Inc. (the "Issuer"), Allergan Sales, LLC ("Parent") and Celestial Merger Sub, Inc. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each outstanding restricted stock unit and

(1) ("Furthaser"), pursuant to which Furthaser was merged with and into issuer (the "Merger"), each outstanting restricted stock unit and any associated rights to the issuance of shares of the Issuer's common stock, par value \$0.001 per share (the "Shares") upon the achievement of Issuer performance goals (the "Issuer RSUs") under the Issuer's equity plans that was not then vested was cancelled, (continued in Footnote 2)

(continued from Footnote 1) and the holder of such cancelled Issuer RSUs became entitled to receive, in exchange therefor, an amount in cash equal to the product of (x) the total number of Shares subject to (or deliverable under) such Issuer RSUs immediately prior to the

- (2) effective time of the Merger (the "Effective Time") (determined after giving effect to the accelerated vesting and deemed achievement at maximum applicable performance levels) multiplied by (y) \$0.67 in cash (the "Closing Amount"). These restricted stock units were fully vested immediately prior to the Effective Time.
- (3) Pursuant to the terms of the Merger Agreement, each option to purchase Shares (a "Company Option") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than the Closing Amount (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an

Edgar Filing: Ramasastry Saira - Form 4

In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled at the Effective Time without any consideration payable therefor.

(4) The Shares subject to this option were fully vested immediately prior to the Effective Time.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.